Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose Study to Evaluate the Safety, Tolerability, and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation

NCT01382797 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT01382797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01382797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose Study to Evaluate the Safety, Tolerability, and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation
Lead sponsor
Alkermes, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
April 30, 2012
Enrollment
157 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-induced constipation